UPDATE 2-US advisers reject new use for J&J/Bayer's Xarelto - Reuters

SILVER SPRING, Md., May 23 (Reuters) - U.S. advisers recommended against expanding the use of Johnson & Johnson's blood thinner Xarelto as a way to reduce the risk of new heart attacks and strokes in people with heart problems. A panel of ...

UPDATE 3-FDA staff sends mixed message on J&J drug Xarelto - Reuters

WASHINGTON, May 21 (Reuters) - U.S. drug reviewers had mixed opinions about whether Johnson & Johnson blood thinner Xarelto reduced the risk of new heart attacks and strokes in people with heart problems, setting the stage for heated debate by ...

J&J’s Blood Thinner Rejected by Panel for Expanded Use - Businessweek

Johnson & Johnson (JNJ) (JNJ) and Bayer AG (BAYN)’s blood-thinner Xarelto failed to win the backing of a U.S. advisory panel for broader use to prevent heart attacks and strokes in patients with a common heart ailment. Advisers to the Food and ...

Bayer’s Xarelto Backed in Final Stroke Guidance From U.K.’s NICE - Businessweek

The U.K.’s National Institute for Health and Clinical Excellence published final guidance recommending Bayer AG (BAYN)’s Xarelto blood-thinner as a cost- effective way to prevent strokes in people with an irregular heartbeat known as atrial ...

FDA review backs Xarelto for big new use in ACS patients - FiercePharma

Xarelto could be one step closer to justifying the aggressive sales projections tossed out by Bayer CEO Marijn Dekkers. The anticoagulant won a thumbs-up from FDA's clinical reviewer, ahead of Wednesday's advisory panel meeting, where FDA ...

Johnson & Johnson Setback Is Positive for Pfizer, Bristol-Myers - Minyanville

The shares are down 7% this year. Wall Street analysts expect Eliquis will be approved and now that J&J has a negative vote from FDA advisers, the odds are that Xarelto’s use won’t be expanded next month. (Eliquis didn’t face an FDA panel.)

FDA panel votes against new use for J&J's Xarelto - Yahoo Finance

WASHINGTON (AP) -- A majority of Food and Drug Administration panelists voted against a new use for Johnson & Johnson's blood thinner Xarelto to reduce life-threatening blood clots. The FDA's panel of experts voted 6-4 Wednesday against the new ...

FDA Panel Votes Against New Use for Blood Thinner Xarelto - Newsday

An advisory panel to the U.S. Food and Drug Administration on Wednesday voted against a new use of a new blood thinner, Xarelto, to cut the risk of potentially lethal clots in people with acute coronary syndrome. The panel of experts voted 6-to ...

FDA Panel Votes Against New Use For Bayer's Oral Blood Thinner Xarelto - Update - NASDAQ

(RTTNews.com) - Bayer AG's (BYR.L, BAYRY.PK, BAYZF.PK) Bayer HealthCare said Wednesday that the U.S. Food and Drug Administration'sCardiovascular and Renal Drugs Advisory Committee voted against the approval of the oral anticoagulant Xarelto ...

FDA advisors recommend against new use for Johnson & Johnson's blood-thinner Xarelto - NJ.com

Advisors to the Food and Drug Administration have voted against recommending approval of Johnson & Johnson’s blood-thinner Xarelto as a treatment for patients with acute coronary syndrome. The New Brunswick-based health care giant’s ...